Testicular Dysfunction Among Cancer Survivors

Angel Elenkov; Aleksander Giwercman

doi:10.1016/j.ecl.2021.11.014

Testicular Dysfunction Among Cancer Survivors

Endocrinol Metab Clin North Am. 2022 Mar;51(1):173-186. doi: 10.1016/j.ecl.2021.11.014.

Authors

Angel Elenkov¹, Aleksander Giwercman²

Affiliations

¹ Department of Translational Medicine, Lund University, CRC; Jan Waldenströms gata 35, SE 214 28 Malmö, Sweden; Reproductive Medicine Centre, Skane University Hospital, Östra Varvsgatan 11F, SE 205 02 Malmö, Sweden.
² Department of Translational Medicine, Lund University, CRC; Jan Waldenströms gata 35, SE 214 28 Malmö, Sweden; Reproductive Medicine Centre, Skane University Hospital, Östra Varvsgatan 11F, SE 205 02 Malmö, Sweden. Electronic address: aleksander.giwercman@med.lu.se.

PMID: 35216715
DOI: 10.1016/j.ecl.2021.11.014

Abstract

In parallel with increased survival rates, quality of life (QoL) has become of growing importance in the management of young cancer survivors. Several surveys have indicated that in those subjects, the issue of reproductive function is considered as one of the main QoL aspects. In this article, we summarize the current evidence, as well as gaps of knowledge and research needs, regarding the impact of cancer and cancer treatment on testicular function-including fertility and androgen production. Also, pre and posttherapy clinical management of reproductive issues in male cancer survivors, are given.

Keywords: Cancer; Cancer therapy; Chemotherapy; Fertility; Hypogonadism; Irradiation; Testicular cancer.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Cancer Survivors*
Fertility
Humans
Male
Quality of Life
Surveys and Questionnaires
Testicular Neoplasms* / drug therapy
Testicular Neoplasms* / therapy